Clinical trials: Stage IV, NSCLC
Squamous Non-small Cell Lung Cancer
Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC
This is a prospective, single arm, multicenter phase II study aimed at evaluating the efficacy and safety of Envafolimab combined with standard platinum containing dual drug chemotherapy and Recombinant Human Endostatin in…
- Trial name
- NCT05243355
- Testing
- "Envafolimab" and "Chemotherapy" and "Recombinant Human Endostatin"
- Where
- 2 sites in China
- Volunteers
- 46 people
- Sponsor
- Qilu Hospital of Shandong University
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)
This is an open-label, randomized, positive drug-controlled Phase Ⅱ clinical study to compare the efficacy and safety of HB1801 to Taxotere in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who…
- Trial name
- NCT05863325
- Testing
- HB1801, Taxotere
- Where
- China
- Volunteers
- 80 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Lung Cancer - Non Small Cell
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
The purpose of this trial is to determine whether Ipilimumab will prolong survival when compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.
- Trial name
- NCT01471197
- Testing
- Ipilimumab, Pemetrexed
- Where
- 13 sites in United States, Belgium and 3 more
- Volunteers
- 9 people
- Sponsor
- Bristol-Myers Squibb
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.
- Trial name
- NCT03087708
- Testing
- Naloxegol, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 660 sites in United States
- Volunteers
- 50 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
This is a Phase I/II, Open Label Study of WSD0922-FU in Combination with Osimertinib for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose disease has progressed with third-generation EGFR-TKI with…
- Trial name
- WAYWIN103 (NCT07206498)
- Testing
- Osimertinib (Tagrisso®), WSD0922-FU
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Wayshine Biopharm, Inc.
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
To investigate the efficacy and safety of BIBW 2992 compared to standard first-line chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation
- Trial name
- NCT01121393
- Testing
- Gemcitabine+Cisplatin, BIBW 2992
- Where
- 36 sites in China, South Korea and 1 more
- Volunteers
- 364 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
Pharmacological Ascorbate for Lung Cancer
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of non-small cell lung cancer (NSCLC) in adults.
- Trial name
- NCT02420314
- Testing
- Paclitaxel, Carboplatin, Ascorbic Acid
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Joseph J. Cullen, MD, FACS
NSCLC (Advanced Non-small Cell Lung Cancer)
EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients
The goal of this registry is to capture real-world data from plasma- and tissue-based molecular profiling, treatments, outcomes and patient-reported outcomes from patients with advanced or metastatic non-small cell lung cancer…
- Trial name
- EMPATHY NSCLC (NCT07096258)
- Where
- 4 sites in France, Italy and 2 more
- Volunteers
- 1,000 people
- Sponsor
- Hedera Dx SA
Non-Small Cell Lung Cancer
Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
This is a multicenter randomized phase II to determine if the administration of standard platinum-based chemotherapy before MK-3475 in with Chemotherapy naive stage IV Non-small Cell Lung Cancer (NSCLC) will improve the overall…
- Trial name
- NCT02591615
- Testing
- MK-3475, Carboplatin, Paclitaxel
- Where
- 11 sites in United States
- Volunteers
- 91 people
- Sponsor
- Alliance Foundation Trials, LLC.
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer
A Study of VET3-TGI in Patients With Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by…
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- STEALTH-001 (NCT06444815)
- Testing
- VET3-TGI, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- KaliVir Immunotherapeutics
Lung Cancer
Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006004
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 16 sites in United States, Australia and 2 more
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer
Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with previously untreated…
- Trial name
- NCT00411047
- Testing
- gefitinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Massachusetts General Hospital
Lung Cancer
Two Rebeccamycin Analogue Regimens in Treating Patients With Advanced or Recurrent Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of rebeccamycin analogue is more effective in treating non-small cell lung…
- Trial name
- NCT00006017
- Testing
- becatecarin
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Case Comprehensive Cancer Center
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after…
- Conditions
- Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT04902040
- Testing
- Atezolizumab, Avelumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC Stage IV, Brain Metastases
Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC
This is a phase II, Open-Label, Multicenter, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined with Pemetrexed/ Carboplatin in Patients with Brain Metastases of Non-squamous Non-small Cell…
- Conditions
- NSCLC Stage IV, Brain Metastases, PD-1 Antibody
- Trial name
- NCT04507217
- Testing
- Tislelizumab, Carboplatin, Pemetrexed
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer
Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
To investigate the efficacy and safety of sindilizumab combined with platinum-containing dual chemotherapy in first-line treatment of elderly patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT06883136
- Testing
- Sintilimab+Cis-platinum/Carboplatin with Pemetrexed or Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Qianfoshan Hospital
EGFR Mutated EGFR TKI Naive Metastatic NSCLC
Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study will evaluate the safety, preliminary efficacy, and pharmacokinetics (PK) of momelotinib (MMB) and erlotinib, as well as define the maximum tolerated dose (MTD) of momelotinib (MMB) combined with erlotinib in adults…
- Trial name
- NCT02206763
- Testing
- Momelotinib (MMB), Erlotinib
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Sierra Oncology LLC - a GSK company
NSCLC Stage IV, Metastatic Non-Small Cell Lung Cancer
Plasma-Adapted First-Line Pembro In NSCLC
This research study is studying to see if a blood test, collected at different times during the treatment of metastatic non-small lung cancer, can be used to detect early response in patients being treated with pembrolizumab and…
- Trial name
- NCT04166487
- Testing
- Pembrolizumab, PEMETREXED, CARBOPLATIN
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Julia K. Rotow, MD
Lung Cancer
Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of chemotherapy with pyrazoloacridine in treating patients…
- Trial name
- NCT00002656
- Testing
- pyrazoloacridine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer, Radiation Toxicity
Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Flaxseed may help protect normal cells from the side effects of radiation therapy.
- Trial name
- NCT00955942
- Testing
- flaxseed
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.